Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;51(5):2554-2563.
doi: 10.3906/sag-2104-227. Epub 2021 Jun 24.

Allergic bronchopulmonary Aspergillosis in children

Özge Atay  1 , Suna Asilsoy  1 , Gizem Atakul  1 , Serdar Al  1 , Özge Kangallı Boyacıoğlu  2 , Nevin Uzuner  1 , Özkan Karaman  1
Affiliations

Allergic bronchopulmonary Aspergillosis in children

Özge Atay et al. Turk J Med Sci. 2021 Oct.

Abstract

Background: Allergic bronchopulmonary aspergillus (ABPA) is a lung disease caused by hypersensitivity from Aspergillus fumigatus. Diagnostic criteria, staging systems and treatment methods for ABPA disease have been reported in studies evaluating populations, the majority of which are adult patients. Our study aimed to discuss the use of ABPA diagnostic criteria in children, the success of other alternative regimens to oral corticosteroids in the treatment of ABPA, and the changes that occur during treatment, in the light of the literature.

Methods: Between January 2017 and 2020, patients diagnosed with ABPA at the Dokuz Eylül University Child Allergy and Immunology clinic were identified; demographic characteristics, clinical and laboratory findings, diagnostic scores and stages, and treatment protocols were analyzed retrospectively.

Results: The mean age of patients diagnosed with ABPA was 14.33 ± 1.96. At the time of ABPA diagnosis, the median total IgE level was 1033 IU/mL (1004-6129), and the median AF specific IgE was 10.64 (2.59-49.70) kU/L. Bronchiectasis was detected in HRCT of 5 cases. We detected significant improvement in spirometric analysis with omalizumab treatment in our patient with steroid-related complications.

Discussion: Today, although risk factors have been investigated for ABPA, it has not been revealed clearly. Both diagnostic criteria and treatment regimens have been described in research studies, mostly adults. In pediatric patients; clarification of diagnosis and treatment algorithms is necessary to prevent irreversible lung tissue damage and possible drug side effects.

Keywords: Allergic bronchopulmonary aspergillosis; asthma; child; cystic fibrosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST:

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
High-resolution computed tomography images of the patients. 1a. Peribonchial thickening, 1b. Cystic areas, 1c. Budding tree sign, 1d. Nonspecific nodule, 1e. Pulmonary infiltration, 1f. Central bronchiectasis.
Figure 2
Figure 2
Spirometric changes in the follow-up of our third case.
Figure 3
Figure 3
Changes in total IgE levels of cases.
See this image and copyright information in PMC

References

    1. Tillie-Leblond I Tonnel AB Allergic bronchopulmonary aspergillosis. Allergy. 2005;60:1004–1013. - PubMed
    1. Hinson KF Moon AJ Plummer NS Broncho pulmonary aspergillosis; a review and a report of eight new cases. Thorax. 1952;7:317–333. - PMC - PubMed
    1. Ritz N Ammann RA Casaulta AC Schoeni-Affolter F Schoeni MH Risk factors for allergic bronchopulmonary aspergillosis and sensitisation to Aspergillus fumigatus in patients with cystic fibrosis. European Journal of Pediatrics. 2005;164:577–582. - PubMed
    1. Rosenberg M Patterson R Mintzer R Cooper BJ Roberts M Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Annals of Internal Medicine. 1977;86:405–414. - PubMed
    1. Greenberger PA Allergic bronchopulmonary aspergillosis. The Journal of Allergy and Clinical İmmunology. 2002;110:685–692. - PubMed

Substances

LinkOut - more resources